| Alex James Jilka, DO | |
|
4401 Wornall Rd, Kansas City, MO 64111 | |
| (816) 932-0340 | |
| Not Available |
| Full Name | Alex James Jilka |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 9 Years |
| Location | 4401 Wornall Rd, Kansas City, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942687165 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 2018010484 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Luke's South Hospital | Overland park, KS | Hospital |
| Saint Luke's East Hospital | Lees summit, MO | Hospital |
| Saint Lukes North Hospital | Kansas city, MO | Hospital |
| St Lukes Hospital Of Kansas City | Kansas city, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Saint Lukes Physician Group Inc | 3577476894 | 1070 |
| Saint Lukes Physician Group Inc | 3577476894 | 1070 |
News Archive
Common substances approved for fumigation, such as phosphine, usually evaporate within a short period of time. If used properly a risk to consumers is therefore unlikely according to current knowledge.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at two upcoming melanoma conferences.
Today, the Society for Cardiovascular Angiography and Interventions (SCAI) launched "WINHeart - Score a WIN for Women," an initiative that raises awareness surrounding gender-based disparities in the diagnosis, treatment and survival of women with cardiovascular disease (CVD).
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent on methods of treating heart failure patients with bucindolol based on genetic testing.
› Verified 6 days ago
| Entity Name | Saint Lukes Hospital Of Garnett Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619901725 PECOS PAC ID: 8729071691 Enrollment ID: O20040406001183 |
News Archive
Common substances approved for fumigation, such as phosphine, usually evaporate within a short period of time. If used properly a risk to consumers is therefore unlikely according to current knowledge.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at two upcoming melanoma conferences.
Today, the Society for Cardiovascular Angiography and Interventions (SCAI) launched "WINHeart - Score a WIN for Women," an initiative that raises awareness surrounding gender-based disparities in the diagnosis, treatment and survival of women with cardiovascular disease (CVD).
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent on methods of treating heart failure patients with bucindolol based on genetic testing.
› Verified 6 days ago
| Entity Name | Saint Lukes Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093263717 PECOS PAC ID: 3577476894 Enrollment ID: O20050302000266 |
News Archive
Common substances approved for fumigation, such as phosphine, usually evaporate within a short period of time. If used properly a risk to consumers is therefore unlikely according to current knowledge.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at two upcoming melanoma conferences.
Today, the Society for Cardiovascular Angiography and Interventions (SCAI) launched "WINHeart - Score a WIN for Women," an initiative that raises awareness surrounding gender-based disparities in the diagnosis, treatment and survival of women with cardiovascular disease (CVD).
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent on methods of treating heart failure patients with bucindolol based on genetic testing.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alex James Jilka, DO 901 E 104th St, Kansas City, MO 64131-4517 Ph: (816) 502-8752 | Alex James Jilka, DO 4401 Wornall Rd, Kansas City, MO 64111 Ph: (816) 932-0340 |
News Archive
Common substances approved for fumigation, such as phosphine, usually evaporate within a short period of time. If used properly a risk to consumers is therefore unlikely according to current knowledge.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at two upcoming melanoma conferences.
Today, the Society for Cardiovascular Angiography and Interventions (SCAI) launched "WINHeart - Score a WIN for Women," an initiative that raises awareness surrounding gender-based disparities in the diagnosis, treatment and survival of women with cardiovascular disease (CVD).
ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent on methods of treating heart failure patients with bucindolol based on genetic testing.
› Verified 6 days ago
Subashis Paul, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 2301 Main St, Kansas City, MO 64108 Phone: 816-395-3558 | |
Tyler Porter, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 | |
Christine M. Sankpill, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 Fax: 816-932-3148 | |
Anuhya Caipa Young, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 Fax: 816-932-3148 | |
David A Wooldridge, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 Fax: 816-932-3148 | |
Peter Lebourveau, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 Fax: 816-932-3148 | |
David C Hermanns, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 2301 Holmes St, Kansas City, MO 64108 Phone: 816-404-1000 |